The humanized monoclonal antibody bevacizumab (Avastin®) has been available in the EU
since 2005. Results of phase III trials demonstrate that adding intravenous bevacizumab to …

Stereotactic body radiotherapy (SBRT) has become a standard treatment option for early
stage, node negative non-small cell lung cancer (NSCLC) in patients who are either …

Introduction We defined “ultracentral” lung tumors as centrally located non–small cell lung
cancers with planning target volumes overlapping the trachea or main bronchi. Increased …

Lung cancer is the leading cause of cancer-related death worldwide, with approximately 1.2
million deaths annually. The standard-of-care in patients with advanced disease is platinum …

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and can be
further classified as nonsquamous carcinoma (including adenocarcinoma, which accounts …

Non-small-cell lung cancer (NSCLC) represents about 85% of all lung cancers, and more
than half of NSCLCs are diagnosed at an advanced stage. Chemotherapy has reached a …

Uveal melanoma (UM) is the most common primary intraocular malignancy in adults.
Important cytogenetic and genetic risk factors for the development of UM include …

Background Limited data are available for the combination regimen of anti-programmed cell
death protein 1 (PD-1) inhibitor and anti-angiogenic agents as second-line therapy for the …

Recognition of the vascular endothelial growth factor (VEGF) pathway as a key mediator of
angiogenesis has led to the clinical study of several VEGF and VEGF receptor (VEGFR) …

Recent successes in immunotherapeutic strategies are being investigated to combat
cancers that have less than ideal responses to standard of care treatment, such as non …